Uncovering the Diversity of Form and Function for Long Non-coding RNAs in Lung Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (15 November 2022) | Viewed by 6273

Special Issue Editor


E-Mail Website
Guest Editor
Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
Interests: long non-coding RNA; lung cancer; DNA damage repair; alveolar epithelial cell biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear colleague,

This Special Issue will encompass recent research into the form and function of long non-coding RNAs (lncRNAs) that play a causal role in the etiology of lung cancer. Lung cancer will be defined broadly to include small cell and non-small cell, as well as all histological subtypes. LncRNAs will be the main subject of this Special Issue, including but not limited to their transcriptional regulation, targeting and being targeted by miRNAs, partnering interactions in protein complexes, mechanisms in the initiation, promotion, and progression of lung cancer. This Special Issue will also encompass the utility of lncRNAs as biomarkers of lung cancer and the effect that specific lncRNAs play on patient outcomes and response to current therapies.

Prof. Crystal N. Marconett
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lncRNAs in lung cancer
  • Mechanisms of lncRNA function
  • Regulatory RNA function
  • Scaffolding RNAs
  • lncRNA signaling components.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 3219 KiB  
Article
Plasma Extracellular Vesicle Long RNA in Diagnosis and Prediction in Small Cell Lung Cancer
by Chang Liu, Jinying Chen, Jiatao Liao, Yuchen Li, Hui Yu, Xinmin Zhao, Si Sun, Zhihuang Hu, Yao Zhang, Zhengfei Zhu, Min Fan, Shenglin Huang and Jialei Wang
Cancers 2022, 14(22), 5493; https://doi.org/10.3390/cancers14225493 - 9 Nov 2022
Cited by 2 | Viewed by 1489
Abstract
(1) Introduction: The aim of this study was to identify the plasma extracellular vesicle (EV)-specific transcriptional profile in small-cell lung cancer (SCLC) and to explore the application value of plasma EV long RNA (exLR) in SCLC treatment prediction and diagnosis. (2) Methods: Plasma [...] Read more.
(1) Introduction: The aim of this study was to identify the plasma extracellular vesicle (EV)-specific transcriptional profile in small-cell lung cancer (SCLC) and to explore the application value of plasma EV long RNA (exLR) in SCLC treatment prediction and diagnosis. (2) Methods: Plasma samples were collected from 57 SCLC treatment-naive patients, 104 non-small-cell lung cancer (NSCLC) patients and 59 healthy participants. The SCLC patients were divided into chemo-sensitive and chemo-refractory groups based on the therapeutic effects. The exLR profiles of the plasma samples were analyzed by high-throughput sequencing. Bioinformatics approaches were used to investigate the differentially expressed exLRs and their biofunctions. Finally, a t-signature was constructed using logistic regression for SCLC treatment prediction and diagnosis. (3) Results: We obtained 220 plasma exLRs profiles in all the participants. Totals of 5787 and 1207 differentially expressed exLRs were identified between SCLC/healthy controls, between the chemo-sensitive/chemo-refractory groups, respectively. Furthermore, we constructed a t-signature that comprised ten exLRs, including EPCAM, CCNE2, CDC6, KRT8, LAMB1, CALB2, STMN1, UCHL1, HOXB7 and CDCA7, for SCLC treatment prediction and diagnosis. The exLR t-score effectively distinguished the chemo-sensitive from the chemo-refractory group (p = 9.268 × 10−9) with an area under the receiver operating characteristic curve (AUC) of 0.9091 (95% CI: 0.837 to 0.9811) and distinguished SCLC from healthy controls (AUC: 0.9643; 95% CI: 0.9256–1) and NSCLC (AUC: 0.721; 95% CI: 0.6384–0.8036). (4) Conclusions: This study firstly characterized the plasma exLR profiles of SCLC patients and verified the feasibility and value of identifying biomarkers based on exLR profiles in SCLC diagnosis and treatment prediction. Full article
Show Figures

Figure 1

Review

Jump to: Research

20 pages, 1604 KiB  
Review
Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression
by Annika Karger, Rajender Nandigama, Albrecht Stenzinger, Friedrich Grimminger, Soni Savai Pullamsetti, Werner Seeger and Rajkumar Savai
Cancers 2021, 13(16), 4127; https://doi.org/10.3390/cancers13164127 - 17 Aug 2021
Cited by 6 | Viewed by 3705
Abstract
Ever since RNA sequencing of whole genomes and transcriptomes became available, numerous RNA transcripts without having the classic function of encoding proteins have been discovered. Long non-coding RNAs (lncRNAs) with a length greater than 200 nucleotides were considered as “junk” in the beginning, [...] Read more.
Ever since RNA sequencing of whole genomes and transcriptomes became available, numerous RNA transcripts without having the classic function of encoding proteins have been discovered. Long non-coding RNAs (lncRNAs) with a length greater than 200 nucleotides were considered as “junk” in the beginning, but it has increasingly become clear that lncRNAs have crucial roles in regulating a variety of cellular mechanisms and are often deregulated in several diseases, such as cancer. Lung cancer is the leading cause of cancer-related deaths and has a survival rate of less than 10%. Immune cells infiltrating the tumor microenvironment (TME) have been shown to have a great effect on tumor development with macrophages being the major cell type within the TME. Macrophages can inherit an inflammatory M1 or an anti-inflammatory M2 phenotype. Tumor-associated macrophages, which are predominantly polarized to M2, favor tumor growth, angiogenesis, and metastasis. In this review, we aimed to describe the complex roles and functions of lncRNAs in macrophages and their influence on lung cancer development and progression through the TME. Full article
Show Figures

Figure 1

Back to TopTop